Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818701 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7450904 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Ammonia Solution, Strong SCHEMBL28224305 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Propionaldehyde SCHEMBL27094320 | 0.88 | ALDH1A1 (0.50) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL1963985 | 0.86 | ALDH1A1 (0.48) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL1963988 | 0.86 | ALDH1A1 (0.48) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Serine SCHEMBL6021449 | 0.84 | SLC7A5 (0.53) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL29742735 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4477148 | 0.83 | FOLH1 (0.65) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL28103641 | 0.83 | FOLH1 (0.65) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| WO-2025030099-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | claimed |
| EP-4387676-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | Sarepta Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2023034515-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | SAREPTA THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-8415449-B2 | Bioresorbable polymers synthesized from monomer analogs of natural metabolites | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-09 | — | — | US | claimed |
| US-20120197001-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-08-02 | — | — | US | claimed |
| EP-2459617-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | Rutgers, The State University of New Jersey (US) | 2012-06-06 | — | — | EP | claimed |
| US-20110275782-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-11-10 | — | — | US | claimed |
| EP-2334712-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | Rutgers, The State University of New Jersey (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2011014858-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-02-03 | — | — | WO | claimed |
| CN-1303991-C | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | WARNER LAMBERT CO (US) | 2007-03-14 | — | — | CN | claimed |
| US-20060014159-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | NEURION PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| EP-1017358-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| WO-1999015136-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| WO-1995001952-A1 | PROCESS FOR SYNTHESIZING O-SUBSTITUTED OXIME COMPOUNDS AND CONVERSION TO THE CORRESPONDING O-SUBSTITUTED HYDROXYLAMINE | THE GILLETTE COMPANY (US) | 1995-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014159-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | KCNN4, KCNC1, HCN4 | ALDH1A1 3649/4885MEN1 4279/4885LMNA 2377/4885 |
| US-20110275782-A1 | BIORESORBABLE POLYMERS SYNTHESIZED FROM MONOMER ANALOGS OF NATURAL METABOLITES | BCAT2, WASF2, THEM6 | ALDH1A1 2477/4885MEN1 2186/4885LMNA 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.